Enter your keywords

Reducing the carbon impact of inhalers across the North of England

This bulletin provides baseline figures on the current Inhaler Carbon Footprint at ICS level in the North of England, in order that systems can identify the level of response to be undertaken. It examines the current carbon footprint attributed to Inhalers in the North East and Yorkshire and the North West. It also analyses the […]

Omalizumab and dupilumab for chronic rhinosinusitis with nasal polyps

Overview Evaluation reports aim to give objective information and guidance on medicines and medical devices to commissioners of health services, prescribers and others. They include efficacy, adverse effects, place in treatment and arrangements for prescribing. Omalizumab and dupilumab are indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe chronic […]

Respiratory System

This report looks at prescribing trends in primary care for the Respiratory System at SICBl and ICB level with particular focus on bronchodilators and corticosteroids. Prescribing data is weighted with QoF registers, and also uses HES data to measure prescribing to outcomes. The report also calculates the potential opportunity cost for respiratory drugs based on […]

Inhaler Carbon Impact Assessment Tool

Overview The NHS Long Term Plan outlines that 4% of the total NHS carbon footprint savings are expected to be realised through a ‘shift to lower carbon inhalers’ equivalent to a 50% reduction in the inhaler carbon footprint. 1,2 The RDTC has developed an inhaler carbon impact assessment tool in response to these targets. It […]

Inhaler carbon footprint; significance, focus & action

The impact of climate change on health is increasing, as global warming continues to rise. 1 Within the health and social care sector, pressurised metered dose inhalers (pMDIs) and breath-actuated pMDIs (BA-pMDIs) have been identified as a significant contributing factor to the NHS carbon footprint. This publication reviews current inhaler prescribing in the context of […]

Comparison of LAMA/LABA inhalers (update February 2021)

Comparison tables are produced for prescribers and medicines management teams. They are designed to assist in prescribing and decision-making within a specific therapeutic area. Long-acting muscarinic antagonists (LAMAs) and long-acting beta2 agonists (LABAs) are available in a variety of combination inhaler devices. This comparison table allows prescribers and other healthcare professionals to easily compare the […]

Comparison of oscillating positive expiratory pressure devices

Oscillating positive expiratory pressure (OPEP) devices are intended to promote clearance of excess mucus secretions in people with respiratory conditions such as chronic obstructive pulmonary disease, cystic fibrosis, and bronchiectasis. This comparison table allows prescribers and other healthcare professionals to easily compare the characteristics of these devices.

Fluticasone, umeclidinium, and vilanterol (Trelegy Ellipta) for COPD

Fluticasone furoate/umeclidinium bromide/vilanterol dry powder inhaler (Trelegy Ellipta®) is a fixed-dose triple combination of a corticosteroid (ICS), a long-acting anti-muscarinic (LAMA)  and a long-acting beta-agonist (LABA) for relief of symptoms in adults with chronic obstructive pulmonary disease. This review is older than 3 years and has been archived. To request a copy, contact nuth.nyrdtc.rxsupp@nhs.net.